{"id":394320,"date":"2020-12-07T08:43:11","date_gmt":"2020-12-07T13:43:11","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394320"},"modified":"2020-12-07T08:43:11","modified_gmt":"2020-12-07T13:43:11","slug":"relmada-therapeutics-announces-initiation-of-phase-3-program-for-rel-1017-as-adjunctive-treatment-for-patients-with-major-depressive-disorder","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-initiation-of-phase-3-program-for-rel-1017-as-adjunctive-treatment-for-patients-with-major-depressive-disorder\/","title":{"rendered":"Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Dec. 7, 2020<\/span> \/PRNewswire\/ — Relmada\u00a0Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced\u00a0that the first patient has been enrolled in the first Phase 3 clinical trial (RELIANCE I) for the Company’s lead product candidate, REL-1017, as an adjunctive treatment for major depressive disorder (MDD).\u00a0 <\/p>\n

\n

\n
\n \"Relmada
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“The initiation of our Phase 3 program for REL-1017 represents a significant operational milestone for our company,” said Sergio Traversa<\/span>, CEO of Relmada Therapeutics. \u00a0“Importantly, the design of the Phase 3 program incorporates valuable guidance from the U.S. Food and Drug Administration (FDA) obtained in our successfully completed End-of-Phase 2 meeting. \u00a0We believe that the reported positive Phase 2 results are indicative of the potential of REL-1017 to treat patients suffering from MDD. We look forward to the availability of top-line results from RELIANCE I in the first half of 2022.”<\/p>\n

“A significant unmet medical need continues to exist for therapeutics that demonstrate a rapid and robust antidepressant effect in patients with MDD, especially for patients\u00a0who\u00a0do not respond adequately to their first line of treatment.\u00a0 We are hopeful for the results of the RELIANCE trials and that in the near future physicians will have access to this novel treatment in their armamentarium ” said Maurizio Fava<\/span>, M.D., Chief of the Department of Psychiatry at Massachusetts General Hospital, and Principal Investigator for the REL-1017 Phase 3 program.\u00a0\u00a0 “This important Phase 3 program provides us with an opportunity to confirm and further show the effect of REL-1017 in the treatment of MDD, a devastating and life altering condition with many sequelae.\u00a0 I am inspired and excited to continue evaluating this promising product candidate in late-stage clinical trials” said Marco Pappagallo<\/span>, M.D. acting Chief Medical Officer of Relmada Therapeutics.\u00a0\u00a0<\/p>\n

Key points of the Phase 3 program agreed upon in discussions with FDA include:<\/p>\n